I have just completed an update on potentially important, stock driving events for Neuralstem (NYSEMKT:CUR) in 2014. The complete report is free to all on my website. The introduction to the report is as follows:
Neuralstem's clinical trial programs and accompanying results for its two key drugs, the neural stem cell product NSI-566 (its lead drug) and its small molecule drug NSI-189, are picking up a good deal of momentum. This year holds the promise for several events that could continue to drive the stock. The purpose of this report is to highlight potential key events of 2014.
Results from the clinical trials of NSI-566 in ALS are the most important near term drivers of the stock. I believe that a paper summarizing the complete results of NSI-566 in its phase I trial could be published in a peer reviewed journal by the lead investigator on the trial, Dr. Eva Feldman. She is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System and an unpaid consultant to Neuralstem. She is also the past President (2013) of the American Neurological Association.
Because of her credentials and the great interest in this program by the neurological community, this paper could lead to much greater awareness of the promising signals of activity seen in phase I, to the benefit of the stock. In regard to the phase I trial Dr. Feldman has said "Collectively, these preliminary results suggest that intraspinal stem cell transplantation of ALS subjects, with no bulbar symptoms, early in the course of their disease, could slow disease progression and even allow for functional improvement."
The entire report is about nine pages in length and is available at no charge on my website.
Disclosure: I am long CUR.